Weekly Update
20 November 2026

Medicinal Cannabis Matters: Friday Roundup - 20 November 2026

Welcome to this week’s Medicinal Cannabis Matters. We’re looking at calls for greater investment in research into women’s pain, the changing popularity of cannabis varieties in the UK and the ongoing discussion around irradiation and quality standards in medicinal cannabis.

5 min read
Medicinal Cannabis Matters: Friday Roundup - 20 November 2026

Medicinal Cannabis and the Research Into Women’s Pain

Experts speaking at the Cannabis Health Symposium in Frankfurt have called on the medicinal cannabis industry to do more to fund research into women’s pain, including conditions such as endometriosis.

Dr Shabnam Sarshar and Professor Sylvia Mechsner highlighted the lack of research designed specifically around women’s biology, despite the significant impact that chronic pain conditions can have on everyday life. They also discussed how hormonal changes and the endocannabinoid system may influence pain responses and treatment.

A small pilot study involving women with endometriosis reported improvements in pain, sleep and other measures of wellbeing following treatment with medicinal cannabis. So, the experts are calling for greater investment in properly designed clinical trials to build a stronger evidence base. It is an important reminder that more research is needed to understand how medicinal cannabis may support women living with chronic pain.

The Rising Popularity of Dessert-Style Cannabis Strains in the UK

A feature from Leafie explores how dessert-inspired cannabis varieties have become increasingly prominent in UK cannabis culture, with names such as Gelato, Wedding Cake, Runtz and Oreoz now widely recognised.

The article traces this shift back to the influence of American genetics, particularly Girl Scout Cookies, which helped popularise sweeter, more complex aroma profiles. Over time, these genetics were crossed and developed into new varieties, with characteristics such as fruity, creamy and confectionery-inspired aromas becoming a significant part of their appeal.

It also looks at the role of terpenes, the naturally occurring compounds that contribute to the aroma of cannabis. Different combinations of these compounds help create the distinctive scent profiles associated with individual varieties.

In a medicinal context, however, strain names and aroma descriptions should not be treated as indicators of clinical effectiveness or suitability. Treatment decisions should always be guided by individual patient needs and specialist medical advice.

The Science Behind Irradiation in Medicinal Cannabis

Irradiation remains a topic of discussion within the medicinal cannabis industry, particularly when it comes to microbial safety, product quality and the potential impact on the plant’s chemical composition.

In this article, James Duckenfield, CEO of Glass Pharms, explores what irradiation does to medicinal cannabis flower and what it does not. The process uses ionising radiation to reduce viable microorganisms, helping products meet required microbial limits. Importantly, irradiation does not make cannabis radioactive.

The article also considers research into how irradiation may affect cannabinoids and terpenes. Findings have varied, with some studies reporting reductions in certain individual terpenes, while others have found little change. Current laboratory findings do not establish that irradiated and non-irradiated flower differ in their effects on patients.

As with any medicinal product, quality and safety depend on a range of controls. Understanding the science behind different processing methods helps support informed discussions about the standards expected of medicines supplied to patients.

This week’s stories highlight the importance of continued research, a better understanding of cannabis compounds and the quality standards that underpin medicinal cannabis treatment.

At Medicann, we believe patients should have access to clear, balanced information and care that recognises their individual needs. Our specialist team supports patients throughout their treatment journey, from the initial consultation through to ongoing care.

If you’re considering medicinal cannabis treatment, you can use our online eligibility checker to find out whether you may be suitable.

Gary Whipp

Written by

Gary Whipp

Chief Executive Officer

Gary founded Medicann in 2019 with a simple goal: to make safe, affordable access to medical cannabis easier for patients. He led Medicann to become the first clinic in Jersey to issue a medical cannabis prescription, and has since grown the business into a trusted network of clinics across the Channel Islands, the Isle of Man and the UK.

Share